Lv6
1760 积分 2023-12-09 加入
PD08: Optimization of narrowband ultraviolet B for psoriasis using a precision‐medicine approach: PHOTO‐OPP study ( PHOTOtherapy Optimisation Protocol in Psoriasis)
3个月前
已关闭
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis
3个月前
已完结
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
3个月前
已完结
Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum
3个月前
已完结
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial
3个月前
已关闭
Pathogenesis of psoriasis and development of treatment
3个月前
已完结
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)
3个月前
已完结
TYK2 as a Therapeutic Target in the Treatment of Autoimmune and Inflammatory Diseases
3个月前
已完结
The JAK-STAT Pathway
3个月前
已完结
Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds
3个月前
已完结
皖公网安备34019202002308
